코미팜
Financials
Valuation Metrics
코미팜's Market Cap is ₩6648B. At end of 2025 it was ₩5238B. Ranked #366 of 2,405 in KR market (top 15%), #119 of 1,627 on KOSDAQ (top 7%), #38 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 16%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 664.85B KRW | KR#366/2,405 Sec#38/231 |
| Revenue | 53.02B KRW | KR#1,746/2,405 Sec#118/231 |
| Net Income | -3.42B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 139.12B KRW | KR#1,558/2,405 Sec#121/231 |
| Net Assets | 74.16B KRW | KR#1,635/2,405 Sec#133/231 |
| Employees | 163 | KR#1,250/2,405 Sec#103/231 |
| Value | ||
| P/B | 8.97x | KR#2,344/2,405 Sec#211/231 |
| P/S | 12.54x | KR#2,293/2,405 Sec#174/231 |
| EV/EBITDA | 387.97x | KR#1,546/2,405 Sec#109/231 |
| FCF Yield | -0.56% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -4.61% | KR#1,783/2,405 Sec#129/231 |
| ROA | -2.46% | KR#1,783/2,405 Sec#126/231 |
| Op. Margin | 3.33% | KR#1,193/2,405 Sec#87/231 |
| Revenue Growth | -3.27% | KR#1,691/2,405 Sec#163/231 |
| Financial Health | ||
| Debt Ratio | 87.59% | KR#1,428/2,405 Sec#168/231 |
| Total Debt | 40.75B KRW | KR#1,085/2,405 Sec#76/231 |
| FCF | -3.71B KRW | KR#1,428/2,405 Sec#113/231 |
| Cash | 21.36B KRW | KR#1,212/2,405 Sec#86/231 |
| Current Ratio | 1.31x | KR#1,374/2,405 Sec#145/231 |
| Net Debt/EBITDA | 10.99x | KR#1,246/2,405 Sec#90/231 |
| Performance | ||
| 1Y Return | 47.52% | KR#175/2,405 Sec#6/231 |
| 1M Return | -9.82% | KR#1,147/2,405 Sec#110/231 |
| From 52W High | -25.06% | KR#299/2,405 Sec#18/231 |
| 1Y MDD | -35.21% | KR#395/2,405 Sec#26/231 |
| Trading | ||
| Volume | 168,582 shares | KR#437/2,405 Sec#49/231 |
| Trading Value | 1.49B KRW | KR#488/2,405 Sec#47/231 |
| Foreign Own. | 3.94% | KR#1,060/2,405 Sec#95/231 |
| Per Share | ||
| EPS | -46 KRW | KR—/2,405 Sec—/231 |
| BPS | 994 KRW | KR#2,301/2,405 Sec#212/231 |
Company Info
Established in 1972 for animal pharmaceutical manufacturing and sales, the company was listed on KOSDAQ in 2001 and produces vaccines and therapeutics at its Siheung-si and Yesan-gun factories. It engages in animal pharmaceutical manufacturing and offers virus and genetic testing research services, conducting overseas business through its subsidiaries. The company expanded its business areas by developing the new drug COMINOX, completing its Osong Bio-complex factory, and obtaining KGMP approval. It is now focused on global sales through a multinational pipeline. COMI Pharm was established in 1972 and is headquartered in Siheung-si, Gyeonggi-do.